Freshfields Advised Camurus On Strategic Collaboration And Licensing Deal With Eli Lilly

Freshfields Advised Camurus on Strategic Collaboration and Licensing Deal with Eli Lilly

Freshfields has advised Camurus on a strategic collaboration and license agreement with Eli Lilly, granting the pharmaceutical giant exclusive global rights to develop, manufacture, and commercialize long-acting incretin products for cardiometabolic health using Camurus’ FluidCrystal® technology.

Under the agreement, up to four Lilly proprietary drug compounds will be developed using the FluidCrystal platform. Camurus stands to receive up to $290 million in upfront, development, and regulatory milestone payments, and up to $580 million in sales-based milestones. Additionally, Camurus will earn tiered mid-single digit royalties on global net product sales.

The Freshfields team was led by Adam Golden (Partner) and Jeff Jay (Partner), with support from Juliana Zhang (Associate) and contributions from Sora Park.

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.